Results 41 to 50 of about 7,748 (215)
Antibody-Based Immunotoxins for the Treatment of Cancer
Antibodies, 2012 Antibody-based immunotoxins comprise an important group in targeted cancer therapeutics. These chimeric proteins are a form of biological guided missiles that combine a targeting moiety with a potent effector molecule.
Nurit Becker, Itai Benhar
doaj +1 more source
Biotherapy, 1991 Immunotoxins (ITs) are chimeric molecules constructed by covalently conjugating monoclonal antibodies (MoAbs) to plant or bacterial toxins (e.g. ricin or pseudomonas exotoxin). The antibody moiety allows specific targeting of ITs to tumor-associated antigens, while the toxin moiety is responsible for cell killing by irreversible inactivation of protein
openaire +4 more sources
Membrane-translocating peptides and toxins: from nature to bedside [PDF]
, 2008 Today, different functional classes of bioactive peptides and toxins isolated from diverse sources of living organisms are known. In medicine, these polypeptides present the potential to be used structurally unmodified or to serve as templates for ...
Hayashi, Mirian Akemi Furuie +5 more
core +1 more source
Ribosome-Inactivating Proteins from Plants: A Historical Overview
Molecules, 2016 This review provides a historical overview of the research on plant ribosome-inactivating proteins (RIPs), starting from the first studies at the end of eighteenth century involving the purification of abrin and ricin, as well as the immunological ...
Andrea Bolognesi +4 more
doaj +1 more source
Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes
Toxins, 2023 The production of therapeutic recombinant toxins requires careful host cell selection. Bacteria, yeast, and mammalian cells are common choices, but no universal solution exists.
Luana di Leandro +3 more
doaj +1 more source
Toxins, 2016 The toxic moiety of almost all protein-based targeted toxins must enter the cytosol of the target cell to mediate its fatal effect. Although more than 500 targeted toxins have been investigated in the past decades, no antibody-targeted protein toxin has ...
Hendrik Fuchs +2 more
doaj +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Expression of an anti-CD33 single-chain antibody by Pichia pastoris [PDF]
, 2005 CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat ...
Emberson, Louise M. +3 more
core +1 more source
Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?
Medicinal Research Reviews, EarlyView.ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca +6 more
wiley +1 more source
An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells
Antibodies, 2013 Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use ...
Daniel A. Vallera, Nate N. Waldron
doaj +1 more source